Lambert-Eaton Myasthenic Syndrome Clinical Trial
Official title:
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Compassionate use of orphan drug 3,4-Diaminopyridine(DAP) in Treatment of Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP is used to decrease the muscle weakness associated with LEMS and hopefully will decrease the need for prednisone and all other therapies that were previously required to control symptoms. How long a patient will take 3,4 DAP depends upon if he/she is seeing benefits from the medication or experiencing side effects that will prevent them from continuation in the study.
3,4-diaminopyridine (3,4-DAP) decreases symptoms of weakness in patients with LEMS, and therefore can be used to decrease the amount of immune modulation therapy needed to provide an equivalent degree of disease control. ;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02970162 -
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
|
Phase 3 | |
| Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
| Recruiting |
NCT06441825 -
Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis
|
||
| Completed |
NCT01511978 -
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
|
Phase 2 | |
| Completed |
NCT00004832 -
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
|
N/A | |
| Approved for marketing |
NCT00872950 -
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
|
||
| No longer available |
NCT02189720 -
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
|
||
| No longer available |
NCT00994916 -
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
|